Anti-Human DR5 (Drozitumab) - Fc Mutedâ„¢
Anti-Human DR5 (Drozitumab) - Fc Mutedâ„¢ (LT705-GRP)
Products
Description
Drozitumab is a monoclonal antibody that specifically binds to human DR5. DR5 is expressed in a variety of solid tumors and hematologic malignancies, which are characteristically resistant to apoptosis. Drozitumab is a proapoptotic receptor agonists (PARA) that induces apoptosis in a variety of human cancer cell lines and xenograft models, both alone and in tandem with other antineoplastic agents.1 Apoptosis of cancer cells triggered by the activation of DR5, occurs without affecting most normal cell types. Anti-Human DR5 (Drozitumab) utilizes the same variable regions from the therapeutic antibody Drozitumab making it ideal for research projects.
Specifications
| Manufacturer | Leinco Technologies Inc |
|---|---|
| Manufacturer Cat# | LT705 |
| Concentration | ≥ 5.0 mg/ml |
| Formulation | This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added. |
| Isotype | IgG1 λ |
| Clone | PRO95780 |
| Applications | Agonist, ELISA, FA, FC, IF, IP, WB |
| Antigen | DR5 is widely expressed in adult and fetal tissues, with notably high expression on tumor cells. |
| Storage | Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. |
| Protein | DR5 |